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In patients with cystic fibrosis (CF), clinical trials are of paramount importance. Here, the current status of drug development in CF is
discussed and future directions highlighted. Methods for pre-clinical testing of drugs with potential activity in CF patients including relevant
animal models are described. Study design options for phase II and phase III studies involving CF patients are provided, including required
patient numbers, safety issues and surrogate end point parameters for drugs, tested for different disease manifestations. Finally, regulatory
issues for licensing new therapies for CF patients are discussed, including new directives of the European Union and the structure of a
European clinical trial network for clinical studies involving CF patients is proposed.
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Improvements in clinical care have resulted in a dramatic
increase in the life expectancy of people with cystic fibrosis
(CF) over the last 40 years [1,2]. In several European
countries, the median survival is between 30 and 40 years.
The aggressive treatment of lung disease and improvements
in nutrition are the major factors in this context. However,
95% of people with CF still die from respiratory failure [1,2].
In addition to optimizing existing therapeutic strategies,
effective new agents need to be identified. There are
currently a number of antimicrobial and anti-inflammatory
drugs in clinical trials and several drugs with potential
efficacy in pre-clinical studies which address the abnormal
pathophysiology of defective CFTR function. The search for
small molecules which correct the mutated CFTR ion
channel in the respiratory tract and in other organs needs
to be intensified through activities in CF research centres and
pharmaceutical companies [3]. It is hoped that the number of
promising drugs for CF patients will increase in the next
10 years.
The clinical phase of drug development in people with
CF, poses increasing challenges for a number of reasons.
Although many European CF care centres have excellent
infrastructure for this multi-organ disease and provide
optimal facilities for clinical trials, the number of CF
patients in these centres may be limited. Many patients are
already involved in clinical trials or other observational
studies. Phase III studies in CF, powered on FEV1, require up
to 1000 patients for comparison of active drug to placebo.
Such numbers may not be easily available, since approxi-
mately only 50,000 CF patients are registered in patient
databases in Europe and North America. However, novel
methods of statistical analysis, for example those using
repeated measures of FEV1 over a 6 month study period, can
reduce the sample size required by over 50% [4]. Age and
disease status of the patient, as well as the availability of CF
centres with the appropriate infrastructure may further
reduce the number of patients for a given clinical trial. It is
estimated that currently ∼30% of all CF patients are
potentially available to participate in clinical trials [5] In
addition clinical trials are regulated by the EU directive on
clinical trials [6]. This requires all studies involving an
investigational medicinal product (IMP) to be registered and
undertaken to the standard set out in this directive. Particular
responsibilities of the sponsor, principal investigator and
care provider concern research governance and appropriate
infrastructure to be in place to ensure high standards in thee
conduct of clinical trials, in particular to protect patient
safety. The increasing bureaucratic demands on researchers
have been identified as an important barrier to research.
The European Cystic Fibrosis Society (ECFS) therefore
wants to build a European Clinical Trials Network (CTN) to
offer a structured cooperation between sponsors and CF care
centres and facilitate the conduct of clinical trials in Europe
in accordance with the EU directive on clinical trials. Thiseffort is in line with the aims of regulatory agencies such as
European Medicines Agency (EMEA) to encourage and
support the development of drugs for orphan diseases such as
CF.
This document describes the results of discussions on
various issues, relevant in the context of clinical trials, during
an ECFS consensus conference, held on March 24–26, 2006
at Artimino, in Italy. Section 2 is a state-of-the-art-survey of
the different clinical manifestations of CF patients for which
drugs have been successfully developed and a critical
discussion where clinical studies and drug development is
needed. Section 3 describes experimental methods and
animal models for pre-clinical testing of drugs for CF;
Section 4 covers study design options for phase II and III
studies in CF. Surrogate end point parameters, patient
numbers, Quality of Life (QoL) questionnaires and safety
issues of drug testing and reporting in CF are discussed;
Section 5 includes regulatory issues for licensing new
therapies for CF, particularly details on orphan drugs
designation. Finally, Section 6 includes the mission
statement and structure of the proposed CTN, its relations
to sponsors, to European Clinical Trials Centres (CTCs) and
other bodies. The aim of this consensus document is to
provide better and more evidence based care of CF patients
in Europe and elsewhere through an increased number of
well designed clinical trails.
2. Current status of drug development for CF
CF is a multi-organ disease. Drug development has
mainly been directed at the treatment of pulmonary disease
and pancreatic maldigestion and malabsorption. Drugs have
been developed in such different areas as anti-inflammatory
drugs, protease inhibitors, antibiotics, quorum sensing
inhibitors, vaccines, mucolytic agents, ion channel blockers
and enhancers and gene replacement. In the treatment of
pancreatic insufficiency, the main focus has been on
developing more effective pancreatic enzymes. Here, the
current status of drug development in CF is briefly discussed
and future directions highlighted.
2.1. Treatment and prevention of infection
The currently accepted paradigm in the lung pathophys-
iology of CF is based on the hypothesis that reduced
mucociliary clearance — as a consequence of a defective
chloride channel-facilitates bacterial lung infection with
opportunistic pathogens [7]. These infections become
chronic due to a phenotypic switch from non-mucoid to
mucoid variants which are resistant to antibiotics and the
innate host response [8–10]. Strategies for antibiotic
treatment have evolved significantly over the past 20 years
[11,12]. There is now better evidence that commonly used
treatments for CF are safe and effective, through large, well
designed clinical trials and systematic reviews, such as those
undertaken by the Cochrane Collaboration.
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exacerbations in CF is well established though significant
questions remain as to optimum combinations, duration of
treatment and frequency of administration [13,14]. Two
different regimens for administering intravenous antibiotics
in CF patients were compared in the TOPIC study, a
randomised controlled trial of once versus three times daily
tobramycin. This study, powered for equivalence, found no
difference in efficacy between the two regimens but concluded
that once daily treatment might be less nephrotoxic in
children [15]. The emergence of multiply resistant clones of
P. aeruginosa, methicillin resistant S. aureus (MRSA) and
species such as Burkholderia cepacia complex organisms
present new challenges for antibiotic treatment [16]. Studies
investigating particular approaches to such treatments have not
demonstrated any advantages of particular regimes or
combinations of antibiotics [17]. A Cochrane systematic
review has found that there was insufficient evidence to
determine whether regular maintenance antibiotic treatment
wasmore effective than treatment “on demand” in maintaining
lung function in CF patients [18]. However a clinical trial of
patients randomised to regular versus on demand treatment
found that both groups received a similar number of courses of
treatment, suggesting that there is a convergence in clinical
management [13,14]. The investigation of issues of clinical
practice such as this may be best addressed using comparisons
of management and care delivery from national and
international patient registries.
Chronic nebulised antibiotic therapy improves lung
function, suppresses bacterial counts and reduces the frequen-
cy of pulmonary exacerbations [12,19]. Early aggressive anti-
pseudomonal antibiotic treatment is effective in clearing
P aeruginosa infection for a number of years [20–27].
However a recent meta-analysis found only three good quality
randomised controlled trials in this context [28]. Eradication
treatment is routine in many CF centres and clinical trials
comparing alternative eradication regimens may be preferable
for pragmatic reasons. Significant questions remain as to the
most effective combinations of antibiotics to use for
eradication. Further multicentre studies on the treatment of
multi-resistant organisms are also urgently needed.
New devices are needed to enhance the speed of drug
aerosolization, given the large number of different therapeu-
tic interventions a CF patient has to carry out daily. New
inhalation devices including more effective nebulisers using
mesh technologies, dry powder inhalers and more effective
formulations of antibiotics, including lipid incorporation are
currently tested to fulfil this purpose. All these new devices
and medications need to be tested in studies of CF patients.
Clinical trials using vaccines to prevent P. aeruginosa
infections have not yet shown convincing results [19].
Ironically, two large phase III studies using a bivalent
P. aeruginosa flagella vaccine [29] and a polysaccharide-
exotoxinA conjugate vaccine [30] have been initiated at a time
when “early eradication therapy”was used by many European
CF centres which led to a reduction of the incidence rate ofchronic P. aeruginosa lung infection in the centres. Conse-
quently, much longer time frames or larger number of patients
have to be envisaged when vaccines are tested in the CF
population and end points such as “chronic P. aeruginosa lung
infection” are chosen. Cross-infection between CF patients has
been convincingly shown to be significantly reduced when
improved hygienic measures and separation regimes have
been implemented in CF centres [31,32].
2.2. Anti-inflammatory drugs
People with CF suffer from chronic lung inflammation and
several endogenous substances involved in inflammation may
harm the airway tissues. This prompted a successful clinical
trial with high dose prednisolone more than 20 years ago [33].
Because of severe adverse effects with systemic steroids and a
proven effect on airway inflammation in asthma, inhaled
corticosterioids have been suggested as a viable alternative
[34,35]. A recent study has demonstrated no deterioration in
lung function or in time to next pulmonary exacerbation after
withdrawal of inhaled steroids [36]. In bronchopulmonary
aspergillosis (ABPA), oral corticosteroids in conjunction with
itraconazole are the treatment of choice at present [37]. This
strategy has in part been extrapolated from the treatment of
ABPA in people who do not have CF. Larger multicentre
studies of ABPA are needed to know if this treatment is
justified or if, for example, inhaled steroids would be as
beneficial, inducing less adverse effects. Another strategy to
avoid adverse effects of corticosteroids is to use non-steroidal
anti-inflammatory drugs. Ibuprofen has been successfully used
in CF patients [38,39]. The beneficial clinical effect of
ibuprofen was particularly observed in mild patients. Howev-
er, this has not become a well established treatment partly due
to gastrointestinal and other side effects and the need to
monitor blood concentrations [40].
Serine protease inhibitors, which neutralise mainly
neutrophil elastase, an enzyme which is present in airway
specimens of CF patients may be of value in reducing
inflammation in CF [19,41–43]. The reported beneficial
effect of aerosolized α1-protease inhibitor derived from a
study in 12 CF patients carried out in the year 1991 [41]. At
the time of writing, this result has not been confirmed by
other investigators. A recent phase II study of transgenic α1-
protease inhibitor failed to demonstrate any important anti-
inflammatory or clinical benefit [44]. A multicentre trail with
EPI-hNE4 has been carried out in CF patients, yet the results
have not been published to date.
Azithromycin has been demonstrated to improve FEV1,
QoL and to reduce exacerbations in randomised controlled
trials [45–48]. These results are most likely due to anti-
inflammatory effects, although this is not confirmed. Several
other anti-inflammatory drugs may have beneficial effects in
CF patients [40] and need to be further evaluated. Pre-
clinical results demonstrated that a metabolically stable
lipoxin analog suppressed neutrophilic inflammation, de-
creased pulmonary bacterial burden and attenuated disease
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cast has been studied in two smaller trials, showing reduction
of serum eosinophilic cationic protein, but conflicting results
on serum IL-8 and clinical outcomes [50,51]. Although
potentially beneficial, anti-inflammatory drugs remain a two
edged sword in CF where phagocytic effector cells are
needed to control airway infection. A recent trial with the
leukotriene B4 antagonist BIIL 284, aimed at reducing
inflammation resulted in an increased rate of pulmonary
exacerbation in patients on active treatment compared to
control patients.
2.3. Treatment of pancreatic insufficiency, nutrition and
liver disease
Pancreatic insufficiency results in a poor nutritional status
which worsens the prognosis of CF patients [52,53]. The
development of acid resistant microspheres for delivery of
pancreatic enzyme preparations has greatly improved the
treatment of fat malabsorption, but in many patients a normal
absorption, even with proton pump inhibitors, is not
achieved [54]. Better pH-independent pancreatic enzyme
preparations need to be developed. Additional interventions
to improve the nutritional state in CF are also necessary.
Interventions may include oral calorie supplements in CF,
enteral feeding by either nasogastric or gastrostomy tubes
[55] and microelements [52]. Although a recent study found
no significant difference between children randomised to
supplements and those given nutritional advice [56], new
approaches to energy supplementation are needed. Neonatal
screening programs detect CF patients within the first few
weeks of life and it is particularly important to optimize
nutritional strategies at this early stage.
CF related diabetes (CFRD) is a major complication in
older patients with exocrine pancreatic insufficiency. The
diagnosis is associated with worse survival and a decline in
lung function and body weight. Early diagnosis and
intervention may lead to improved prognosis, but further
studies are required to answer important questions such as
the optimum time to start treatment and whether oral
hypoglycaemic agents are beneficial prior to starting insulin
[57,58].
A further major complication is osteoporosis [59,60]. The
cause of osteoporosis is multifactorial, including the effects
of chronic inflammation, cumulative use of steroids, lack of
exercise, impaired lung function and nutritional deficiencies.
Clinical trials are needed to define the optimal treatment
strategy for CF related osteoporosis, including the develop-
ment of guidelines on follow up therapy [61]. Ursodeoxy-
cholic acid (URSO) has been shown to normalise elevated
liver enzyme levels in CF liver disease [62]. However, its
long-term effect on the evolution of liver disease remains
largely unknown. Since liver disease is a life limiting factor
in only a few patients, multi-national studies are needed to
determine the efficacy of URSO and other potential drugs for
liver disease in CF.2.4. Drugs correcting mucus viscosity
Due to the basic defect, water is extensively re-absorbed
from the apical side of the respiratory epithelial cells in CF,
leading to a highly viscous mucus layer on the respiratory
epithelium. In addition, as a consequence of persisting bac-
terial pathogens, sputum plugs are created by the high
numbers of decaying neutrophils in the airway lumen.
Sputum obstructs the airways and reduces lung function. To
reduce sputum viscosity, recombinant human DNase has
given favourable results in several clinical trials [63–65]. It
improved pulmonary function and reduced the number of
pulmonary exacerbation in CF patients with moderate and
mild lung disease. To re-constitute water to the airway
surface liquid, hypertonic saline has been successfully used
in CF patients, reducing exacerbations and improving lung
function [66,67]. Furthermore, UTP analogues may enhance
mucosal hydration and mucociliary clearance. A double-
blinded phase II inhalation study of INS37217 in patients
with mild CF lung disease revealed promising results [68]
Also Moli1901, an activator of the calcium dependent
chloride channel, is thought to improve mucociliary clear-
ance and was shown to be safe in CF patients [69,70].
2.5. Pharmacological treatment of CFTR
Intracellular production, trafficking or activation of CFTR
are possible targets of therapeutic interventions [7,71,72]. A
successful example is the aminoglycoside gentamicin which
increased the production of CFTR mRNA in CF patients
carrying Class I mutations [73,74]. Certain chemical
chaperones, such as phenylbutyrate, CPX and glycerol
have been shown to increase F508del CFTR folding in vitro,
and restore CFTR function including chloride transport at the
cell surface [75]. However, efficacy with an acceptable
safety profile in patients with CF has not yet been
demonstrated. The same is true for the flavonoid genistein
which interacts directly with the nucleotide binding domain
2 to stabilise the open channel configuration of CFTR [76],
and vitamin C which regulates CFTR-mediated chloride
secretion in epithelia [77]. High throughput screening
technology is currently being used in the search for new
compounds that either rescue the cell surface expression of
mutant CFTR (termed CFTR correctors) or enhance the
activity of mutant chloride channels present at the cell
surface (termed CFTR potentiators) [3,78].
2.6. Gene replacement therapy
Several clinical trials have been carried out in CF patients
to restore CFTR function by transfecting mutant CFTR
expressing cells with wild type CFTR [79]. Successful gene
transfer has been demonstrated, though effects on CFTR
function were modest and temporary. Improved gene transfer
agents and plasmids have been developed and clinical trials
are likely in the near future [80].
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3.1. Which in vitro models are useful for drug testing?
Pre-clinical testing of drugs with potential activity in CF
patients is an essential step in drug development. This
implicates a thorough knowledge of the methods to test the
activity of the drug in question [81]. Experimental protocols
for human and murine airway cell cultures are available [82–
84]. For testing drugs which improve CFTR function
(correctors, potentiators), the following cell lines are useful:
Fischer rat thyroid (FRT) epithelial cells, stably transfected
with human dF508 CFTR+YFP construct [3] or with dF508
CFTR or G551D CFTR and grown as monolayers on filters
[85]; NIH-3T3 mouse fibroblasts or C127 mouse mammary
epithelial cells, stably transfected with human dF508-CFTR
[3,85,86]; CFBE41o-cells (CF bronchial, homozygous
dF508 CFTR), parental, grown on coated permeable filters
or collagen-coated plastic [87], or stably lentiviral-trans-
duced with WTor with dF508-CFTR [88]; BHK cells, stably
transfected with human dF508 CFTR [89] or dF508 CFTR-
3HA [90], or stably lentiviral-transduced with WT or with
dF508-CFTR [91]; CFT1-C2dF508; CFTE29o-(CF tracheo-
bronchial); CFNPE14o-(CF nasal polyps); CF-KM4 (serous
airway cells); and CF15 or IB3 cells (CF nasal, co-
expressing ENaC channels) [71,91,92]. Additionally, differ-
ent cell models, expressing N-terminally GFP-tagged human
dF508 CFTR, have been described [93].
Furthermore, CHO-mouse and human dF508-CFTR cells
are available, air–liquid interface cultures of human tracheal
and bronchial epithelial (HBE) cells (±co-cultures with
neutrophils) [85,91], native airway epithelial cells from nasal
brushings [71], and ex vivo muscle-stripped intestinal
mucosa [94]. Finally, CF airway tissue has been used in a
xenograft model [95,96], and pig and human airway serous
glands are available [97,98].
The detection of CFTR in human and murine tissues
[99,100] and in cells obtained by nasal brushings [81] has been
published as well as techniques for the study of CFTR protein
in vivo [101] and in vitro. CFTR folding assays have been
established [102–104]. Antibodies with specificity for CFTR
have been evaluated [99]. Drugs which correct CFTR function
can be tested using the electrophysiological patch-clamp
technique [105], the Ussing chamber [106], fluorescent dyes
and radioisotopes [107,108]. For gene replacement therapy,
suitable gene transfer agents and expression plasmids have
been described [109]. For testing mucolytics, no standard
assay is available. P. aeruginosa isolates from CF patients are
tested using routine susceptibility testing of antibiotics. To
mimic the interaction of antibiotics with bacterial biofilms
microtiter assays have been developed [17,110].
3.2. Which animal models are useful for drug testing?
Animals which mimic CF disease are an important
cornerstone for drug testing in CF [111]. Transgenic micecarrying Cftr mutations have been generated [112–118].
These include homozygous dF508 CF mice in different
backgrounds (FVB, C57/Bl/6, Balb-C) [94], Cftr-KO mice
[80], human WT-CFTR knockin CFTR−/− mice with
the FABP intestinal promoter to prevent DIOS (Cftrtm1Unc-
TGNFABPCFTR mice [119], hG542X knock-in mice
[73], Cftrtm1G551D mice, Cftrtm2Hgu, carrying the G480C
mutation.
Congenic CFTR-knockout mice develop a lung disease
with signs of fibrosis and recruitment of inflammatory
cells. However, lung cultures of these congenic CFTR−/−
mice showed no growth of pathogenic organisms [120,121].
Although infectious lung disease can be established in murine
CF models, either the pathogen has to be repeatedly admin-
istered to the animals [115], an extremely high P. aeruginosa
cfu has to be used [117] or the inoculum has to be embedded in
agar or alginate beads and introduced into the lungs by
trachostomy [122].
Another difference of murine CF models as compared to
humans concerns drug clearance [123].Mice are also available
which over-express the sodium channel EnaC and show CF
like lung disease [124]. The described mouse models have not
been used until today for gene therapy or pharmacological
interventions. This is most probably due to the lack of potent
antibodies, specific for mouse CFTR, and other end points for
clinical trials. Consequently, alternative animal models of CF
in larger species such as the pig and ferrets are currently
developed [125]. Given its gross anatomical, histological and
physiological similarities to humans, the pig may be par-
ticularly useful in this context [126]. Animals models of
chronic P. aeruginosa lung infection have been developed
[122,127]. Animal models for CF-related diabetes/liver
disease are missing.
4. Study design options for drug development in CF
An essential requirement for good clinical trials in
phase I and II is a valid study design which takes into
account the specific disease process in CF patients,
sufficient patient numbers, appropriate inclusion/exclusion
criteria, meaningful and reliable outcome measures, core
laboratories to measure specific variables, and appropriate
analysis. Furthermore, the design of clinical trials in CF
requires a multidisciplinary approach including clinicians,
statisticians, pharmacologists, nurses and patients and
their representatives. As pharmacokinetics may be differ-
ent in CF, phase I studies should be undertaken in people
with CF before progressing to phase II. The size of
clinical trials conducted in CF patients has often not been
large enough to be able to answer important questions
[128]. The Clinical Trial Network (CTN) (see Section 6)
will insure that clinical trials are conducted in the best
possible manner, involving a panel of European expert
physicians, biostatisticians and scientists. The following
chapter describes outcome measures and study designs for
clinical trials in CF patients.
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CF patients?
Studies in patients with CF are particularly challenging
because of the progressive nature of the disease and a
wide variation in severity and number of organs involved
that influences the outcome of drug testing considerably.
Confounding factors for which patients may be stratified
include their class of mutation, age, gender, bacterial lung
infection, lung function, pancreatic function, hepato-biliary
disease and nutritional status. The most relevant and robust
end point for interventional studies in CF patients is survival.
However, apart from studies using historical controls [129],
the use of survival as an end point is no longer appropriate as
it would take enormous numbers of patients and many years
to see an effect. Thus, surrogate end points and biomarkers
are needed. This may pose problems since CF is a com-
plicated disease and drugs generally only ameliorate
symptoms rather than lead to a radical change in the disease
progression. For example, antibiotic therapy regimes will not
lead to eradication of P. aeruginosa in the chronic infection
state. Thus, it remains difficult to choose a meaningful end
point for a clinical trial.
In the treatment of lung disease in CF, forced expiratory
volume in 1 second (FEV1) and the number of exacerbations
have been accepted by the regulatory agencies EMEA
and FDA based on published clinical trials [11]. Since
lung function is maintained at a higher FEV1 level in an
increasing number of CF patients and on average now
decreases by less than 1%/year [130] clinical trials will be
increasingly restricted to adults if this end point is chosen.
Alternative endpoints, measuring lung function which are
more sensitive to disease severity and change following
treatment are needed.
A reduction of the number of exacerbations during
treatment of lung disease is another accepted end point. The
frequency of pulmonary exacerbations is also declining with
the use of rhDNase, nebulised antibiotics, macrolides and
hypertonic saline and this should be considered in sample
size calculations. At present, FEV1, time to or frequency of
pulmonary exacerbations and QoL assessments are consid-
ered to be the three most robust clinical endpoints. A number
of other surrogate endpoints such as CT scan changes,
exercise tolerance, sputum volume/weight and cough
frequency may be useful and may lower the numbers of
individuals required for particular studies. Biomarkers of
disease such as nasal potential difference and measurements
of inflammation are more problematic to use as endpoints.
There is usually a high variability in these measures and it is
unclear how much change in any of these is required
to correlate with an improvement in clinical outcomes.
Pulmonary exacerbations have been used as both a primary
and secondary end point in CF trials and have been the basis
of regulatory approval of both drugs and biologics.
Exacerbations can be measured as the number over a fixed
period or as time to the first event. A major issue is how todefine “exacerbation”. Historically, it has been defined by
the use of antibiotics or hospitalisation. However, since this
is at the judgment of a treating physician, differences likely
occur between sites. Alternatively, strict definitions have
been developed to define an exacerbation on clinical criteria.
The problem with this approach is that physicians caring for
CF patients have in general become more aggressive using
early antibiotic therapies to prevent a potential hospitaliza-
tion. Thus, many patients may not reach specified criteria. A
preferable solution is to require the presence of symptoms
that have are highly predictive of an exacerbation which
permits early therapy for the patient while achieving uni-
formity of the end point [131].
QoL or patient reported outcome end points are important
for gaining marketing authorization and should be included
in all phase III trials, although it remains unclear at present,
how they should be formulated. Whereas the FDA requests
such end points to be included in pivotal trials, the EMEA
remains less restrictive. Where possible, CF specific
instruments should be used. In international trials it is advis-
able to stratify by country to control for any cultural
differences in reporting QoL [132] (Table 2).
In phase II trials, several surrogate end points and markers
of biological activity and physiologic function are of interest.
The selection of certain biomarkerss depends on the disease
manifestation targeted. For instance, a change in proteolytic
activity of sputum with anti-protease therapy may represent
the primary end point, whereas the clinical efficacy and
further biological activity measures are used as secondary
end points. The reason for this is that the measurement of the
biological activity directly addresses the change made by
the intervention, i.e. reduced proteolytic activity after the
application of an anti-protease. No biomarkers have been
accepted by the authorities. Thus, after a phase of basic
research and proper evaluation in CF studies, demonstrating
the link between the biological activity and a clinically
meaningful outcome, it is advisable to discuss the use of such
markers again with the authorities.
Particularly, when markers are determined more than
once, invasiveness of the applied technique is of concern.
Non-invasive techniques are highly desirable. Inflammatory
markers can be assessed in exhaled air or in collected breath
condensate. The markers, measured in exhaled breath
condensate so far, are all biomarkers of inflammation, thus
again surrogate outcomes. The multiple-breath inert gas
washout technique can distinguish between CF children and
unaffected controls and between children with CF who have
pulmonary infection with P. aeruginosa and those who do
not [133]. However these methods are currently not
sufficiently standardized and validated and thus not accepted
as important end points. Furthermore, the requirement for
specialist equipment may limit their use in multicentre trials.
Table 1 provides a list of possible surrogate markers for CF
clinical studies.
A problem in conducting clinical trials in CF is that
many CF patients are not antibiotic naïve. Prior use of an
Table 1
Outcome measures in clinical trials of CF patients
Outcome measure Treatment target Reference Phase I Phase II Phase III Phase IV
Aerosol deposition ID, GT, P, I, MV, T, [139] +++ ++
Airway surface liquid height GT, P, MV [10]
Blood glucose
Body mass index NL
Bronchial PD GT, P, I, MV, T, [140] +++ ++
Bronchial brush, bronchial lavage fluids, cells ID, GT, P, I, MV, T, [141,142] +++ ++
Chest CT, MRI, HRCT ID, GT, P, I, MV, T, [143,144] +++ +++?
Chest radiograph ID, GT, P, I, MV, T, [143,144] ++ +++
Exercise testing MV, T, [145] ++
Exhaled air and breath condensate analysis [146–148] ++
Fat/nitrogen absorption NL
Frequency of pulmonary exacerbations V, ID, GT, P, I, MV, T, [131] ++ +++
Illness severity score ID, GT, P, I, MV, T, NL [149] ++ +++
Infant and toddler lung function ID, GT, P, I, MV, T, [133,150] +++
LCI/gas mixing
Liver enzymes
Lung function (Spirometry) V, ID, GT, P, I, MV, T, [11] +++ +++ +++ +++
Mucociliary clearance P, MV, T, [67] +++ ++
Nasal brush, nasal wash fluids, cells ID, GT,P, T, [151] +++ +++
Nasal/intestinal PD GT, P, T, [152–54] +++ +++
Quality of life a V, ID, P, I, MV, T, NL [132,155–163] ++ +++ +++
Serum levels of drug ID, P, I, T, NL [11] +++ +++ ++
Serum antibody titers V, [164–166]
Serum markers of inflammation ID, P, I, T, NL [167] +++ +++
Sputum cells nd inflammation markers ID, GT, P, I, MV, T, [168] +++ ++
Sputum volume ID, GT, P, I, MV, T, +++ ++
Sputum microbiology V, ID, GT, P, I, MV, T, [169] +++ +++ +++ +++
Stool Fat
Symptom score ID, GT, P, I, MV, T, NL [170] +++ +++ +++ +++
Weight, height, skin-fold thickness, Arm muscle circumference V, ID, P, I, MV, T, NL [11] +++ +++ +++
Abbreviations: V: vaccine; ID, anti-inflammatory drugs, GT: Gene therapy; P: pharmacological CFTR treatment; I: infection, MV: mucus viscosity; T: Lung
transplantation; NL: pancreatic insufficiency, nutrition and liver disease.
a See also Table 2.
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or bacterial cell numbers in patients with moderate to
extensive lung disease. This presents some problems in
equivalence trials which compare current therapy with new
drug of a similar class. A further problem concerns routine
medication, which is not likely to be changed in CF patients
when a new treatment is tested, particularly, when the new
therapy is cyclic as for instance the use of TOBI. Thus, in
long-term trials of greater than 28 days that compare
monotherapy of inhaled antibiotics, routine medication may
confound the analysis of lung function change or bacterial
numbers. CF is a condition in which the therapeutic burden
is considerable and equivalence studies have an important
role in evaluating treatments which may have similar
efficacy, but where one treatment is more convenient or less
toxic than the other [15].
4.2. Which is the optimal study design?
An “optimally designed” trial will probably never occur
in reality, since there is always a disconnect between doing as
much as possible in a given trial, using a finite patient
population, and getting the trial done in as short a span oftime as possible. However, to optimize a trial, one must keep
in mind the following:
(1) The selection criteria must be broad enough to keep
enrolment moving but still be stringent enough to
obtain the answer to the clinical questions that are
being asked. These criteria should also be customized
for early versus late stage disease, mutation or age etc.
(2) Early studies are usually easier to performwith regard to
general primary variables such as PK levels or safety.
But as the clinical development moves forward, a mea-
surable, relevant end point(s) needs to be defined.
Ideally a scoring system is needed that could correlate
clinical efficacy and QoL measures.
(3) The trial design should not be so complicated that it is
acceptable only to a minority of eligible patients. For
example, a trial that needs serial PFTs and PK blood
draws, repeated often during the course of the trial, is
not likely to succeed. This sort of trial is best handled
with a small number of patients in a specialized setting.
(4) Since the CF community has a limited number of pa-
tients, this limited resource has to be utilized effectively.
The number of patients needed to obtain an answer for a
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designing the study. A crossover design works well in
that it uses less patients, each patient can act as his/her
own control and the data are generally less variable.
However, this design can take longer based on the length
and number of treatment and washout periods. There is
also the risk of a patient having an exacerbation during
one of the arms of the study and discontinuing the
participation in the trial.
A parallel group design is preferable to the crossover
design in CF. The most important argument against
crossover designs are carry over effects, seasonal
variation, patient inconvenience of multiple visits and
the inherent instability of CF lung disease. Time series
designs, in which the participants serve as their own
control and a concurrent control group is missing, may
have additional disadvantages including learning
effects, regression to the mean and secular trends.
Randomization of matched pairs is a strategy for bal-
ancing baseline confounding variables that requires
selecting pairs of subjects who are matched for
important factors like age and sex. Simple randomisa-
tion may not always be appropriate in studies CF.
Stratification of randomisation allows a balance to be
maintained for predetermined important factors which
may impact disease progression. Factors such as age,
gender, lung function or infecting organisms may be
used for stratification. Non-inferiority studies are
equivalence studies designed to detect that the efficacy
of a drug is not inferior to that of another drug in the
same class and are usually hoping to find some advan-
tage in secondary endpoints such as less side effects,
better acceptability to patients or less development of
resistance in the case of antibiotics. Analysis of non-
inferiority studies involve the use of a one-sided
equivalence test, rather than two-sided. The key to
such trials is determining a pre-specified margin of the
end point, which determines non-inferiority, the δ. This
δ is sometimes set in the same range as the improvement
which would be seen in a placebo controlled trial.
Non-inferiority studies have the advantage that they
allow comparison to conventional treatment but have a
number of disadvantages. The number of subjects
necessary in such trials is usually larger than the number
of subjects required for conventional parallel group
trials. There is no comparison to placebo and it is im-
portant that the difference from the comparator is care-
fully defined. Such studies are particularly useful where
it is unethical to compare treatment against placebo.
However, unless the new treatment, for which equiva-
lence or non-inferiority is being sought, offers an
advantage in other directions (safer, more convenient
to administer) it is doubtful that such a trial would be a
good use of limited resources. Naïve patients may be
needed for an equivalence trial, as the comparator may
have lost efficacy and the new agent may then be judgedequivalent. However, it too may not be as efficacious as
the comparator was when used in naïve patients.
(5) More Ethics Committees and IRBs are requiring that
trials have an active control or, at the very least, have
the “usual standard of care” plus the study medication.
If a placebo controlled trial is mandated, or a medi-
cation has to be taken out of the patient's normal
regimen, enrolment could take longer. Balance is
needed between what is needed to have a successful
trial and what the enrolment rate might be. It should be
noted that comparing a new treatment with placebo,
and not best available therapy, is answering at great
expense and inconvenience a question that clinicians
may not be interested in asking.
(6) Clinical trials in CF sometimes need to compare
changes in formulation or a directly competing treat-
ment, for example, new inhaled or alternative inhaled
antibiotics. In these situations equivalence trials may be
appropriate. These trials may demonstrate bio-equiv-
alence when the same drug is being compared with two
different formulations. In such types of studies a
pharmacokinetic (PK) approach is used. Clinical
equivalence studies are more complicated. A true
equivalence study is usually set up as a parallel group
RCT, though it can be a crossover design. Shorter term,
placebo-controlled trials, allowing establishment of
efficacy, followed by longer open label experience for
safety evaluation, may be an acceptable compromise.
4.3. How many patients are needed for phase II and phase
III studies according to a given study design?
The number of patients needed for a given clinical study
depends on the variation of the primary efficacy variable. It
is not possible to determine exact numbers for phase II
clinical trails. They are likely to require 50–100 patients but
will be very dependent on the primary endpoint for any
particular trial. For phase III studies, the numbers required
for particular studies, will also depend on the primary
endpoint. Primary outcome measures such as FEV1, time to
next pulmonary exacerbation, or QoL measures usually
require between 200 and 600 patients. A significant effect on
the number of subjects necessary, i.e. a reduction in patient
numbers with a longer duration of a trial, comes into play
only when the length of a study extends beyond 2 years. The
duration of phase I and phase II clinical trials is usually
determined by the expected time to see a change in the
primary and secondary outcomes. Phase III trials are often
longer in duration in order to allow adequate time to evaluate
the safety profile of the particular drug. In order to detect a
difference between two groups, it is important to know the
standard deviation of the primary endpoint variable.
Assuming that the standard deviation of the variable, e.g.,
FEV1, is ∼15% of predicted and one wants to detect a
difference of 10% between the two groups (unpaired t test,
significance level (alpha)=0.05 (two-tailed)), one needs
Table 2
Countries of validation of Quality of Life Questionnaires (QoL) and
patients' ages for which QoL is used
Country in which QoL
has been validated
Patients' ages for which
QoL is used (years)
References
7 European Nations 8–16 [156]
UK 16+ [157]
Germany 16+ [158]





93G. Döring et al. / Journal of Cystic Fibrosis 6 (2007) 85–99∼35 subjects in each group to conduct the trial with a power
of 80%. If one wants to detect a difference of 6%, one needs
∼100 subjects in each group. The smaller the difference to
be detected, the larger the sample size or a lower power has
to be accepted. These calculations can be easily made with
simple programs. For equivalence studies it is important to
use the appropriate methods for calculating the statistical
power of the study and the sample size [134; http://:home.
clara.net/sisa/instr.htm].
4.4. How is safety of new medicines defined and reported in
CF?
In clinical trials involving CF patients, patient's clinical
status may vary from almost asymptomatic to severely
affected. This may pose a problem regarding the reporting of
serious adverse events during studies, since under current
definitions, every time a patient is hospitalized, it counts as a
serious adverse event. Acute respiratory exacerbations are
therefore considered in some interventional trials not as
serious adverse event, but regarded as an endpoint. People
with CF are taking multiple and diverse medications and,
combined with progression of disease, may make them prone
to develop serious adverse events. People with CF accept a
greater degree of risk over benefits, because of the morbidity
and high mortality of this condition. It is important to collect
and disseminate nominative data on laboratory parameters
and adverse event profiles in the CF population. This data
will facilitate development of appropriate eligibility criteria
for study participation and provide baseline safety data for
comparison during administration of therapeutic agents. A
database of current clinical trials in CF would be helpful and
may provide a way to monitor adverse events. All clinical
trials in CF should be registered on a clinical trials website
such as for the European Union: https://eudract.emea.eu.int/
eudract/ or North America: clinicaltrials.gov.
5. Regulatory issues for licensing new therapies for CF
5.1. What are the benefits of orphan drugs status and how it
is reached?
All clinical trials in Europe must be in line with ICH-GCP
standards, according to the European Union Clinical Trials
Directives [6]. There may be important other regulatory
issues in each member country in relation to research
governance within the research institution and submission of
clinical trials to independent ethical review boards. Appro-
priate licensing with each country's medicines and health-
care regulatory authority are also important.
After the US “Orphan Drug Act” in 1983, the Japanese
“Orphan Drug Legislation” in 1993, the Australian “Orphan
Legislation” in 1998, the European Union has set up similar
incentives for development and market authorization of drugs
for rare diseases, beginning in December 1999 [135,136]. The
Regulation on orphan medicinal products is reserved formedicinal products for human use only, but not for medical
devices, food or food supplements, or medicinal products for
veterinary use. It has been designed for drugs, aimed to treat,
prevent or diagnose life-threatening or very serious diseases
affecting less than 5 individuals in 10,000 in the Community. It
also concerns drugs for which revenues after marketing would
not justify the necessary investment for its development.When
authorised methods for treatment, prevention or diagnosis
exist for a given disease, the applicants should justify that the
product provides a clear benefit to patients.
The current systems have encouraged many smaller and
medium sized companies and academic institutions to
embark on the development of new medicines for CF. The
main EU incentives for sponsors for reaching orphan drug
designation include (1) 10 years exclusivity from the date of
marketing authorisation, (2) protocol assistance from the
EMEA, (3) direct access to the centralised procedure, (4) fee
reduction for centralised applications, (5) priority access to
EU research programs, and (6) national incentives.
Since November 2005 designated orphan medicinal pro-
duct can be authorised only through the centralised proce-
dure. Sponsors can apply for orphan designation [135] at any
stage of drug development, but always before having applied
for marketing authorization. However, orphan drugs desig-
nation can also be sought for “old”, already authorised, drugs
for which a new indication is investigated in rare diseases.
Some pre-clinical and/or clinical data to support the rational
of the application are generally required. Designations have
been made based exclusively on in vitro data in cases where
the data strongly supported the applicants' intention to treat,
diagnose or prevent a rare disease. The application for orphan
designation should also include details of any existing
diagnosis, prevention or treatment methods, e.g., authorised
medicinal products, medical devices and other approaches,
such as surgical interventions, radiological techniques, diet,
physical means. It is important to include a justification as to
why existing methods are not satisfactory or why a significant
benefit can be reached with the drug in question.
Orphan drug applications are examined by the Committee
for Orphan Medicinal Products (COMP) which consists of a
chairperson, one member per EU member state, three repre-
sentatives from patients groups, nominated by the European
Commission, and three members, proposed by the EMEA to
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COMP appoints experts that contribute to the opinions on
designation. The COMP also advises the European Commis-
sion on general EU policies, and international co-operation in
the field of rare diseases.
This program has been increasingly used for drug
development in the context of rare diseases: From 29 appli-
cations received by EMEA since April 2000 for obtaining
orphan drug designation for CF, 21 were granted. Six appli-
cations had been withdrawn and two are still under assessment.
For the designated products 13 procedures for protocol
assistance have been initiated for 11 products. Unfortunately,
the criteria for orphan designation are not internationally
harmonized. For instance, in contrast to FDA, EMEA does
not offer grants for development of products to treat CF and
sponsors do not receive tax credit for clinical research expenses
and it would be of great benefit if a similar system would be
adopted in Europe. Thus, an application should be made to the
European Commission to link the Orphan Disease Programme
to the Framework Granting Programme. There is still a
significant bottleneck in development of drug treatments for CF.
5.2. What are the European Union directives on clinical
trials in adults and children and how does the European
Union support those studies?
Since the symptoms of CF start very early in childhood,
clinical studies must involve children. Most CF children are
prescribed drugs which either do not have a marketing autho-
risation for use in children or are used outside the terms of this
authorisation [137]. Drugs may not be available in formula-
tions which are suitable for children. This is major a problem,
since the evidence for the use of many drugs in children is
inadequate. Considerable work has been undertaken in the last
5 years to remedy this situation. A new programme aims to
provide incentives for pharmaceutical companies to undertake
appropriate research on the efficacy and safety of new and
existing medications in children has been adopted [138], and
the proposals should become law by 2007. It will automat-
ically become law in member states.
Importantly, a new Paediatric Committee set up. Article 4 of
the Council Common Position concerns the composition of the
Paediatric Committee. All members of the EUwill be invited to
nominate two representatives, one of whom will be chosen. In
addition, there will be three places for health professionals
and three places for patients' representatives. Members will be
chosen by the Commission after a call for expressions of
interest, likely to be published in Autumn 2007. This committee
will have a large number of very important functions:
1. The scientific assessment and agreement of a detailed
paediatric investigation plan (below), and monitoring its
implementation;
2. The agreement of waivers and deferrals (below), the
monitoring of compliance with the plan, and ensuring that
all data is in the public domain;3. To provide free scientific advice to those interested in
developing medicines for children. The committee will be
concerned to foster good studies, and avoid unnecessary
ones. Ethics will be dealt with under existing provisions;
4. They will administer a Paediatric Use Marketing Autho-
risation (PUMA) a separate category for products ex-
clusively designed for use in children;
5. They will monitor adverse effects — and part of any
application will have to be a plan for gathering data on
these. In particular high risk situations, specific studies
may be required to be put in place;
6. There will be a European wide clinical trials registry;
7. The committee will develop an inventory of paediatric
needs, which will set the research agenda in the EU;
8. There will be a network of centres doing clinical studies
set up within Europe;
9. There will be an increase in the high quality information,
available concerning medicines for use in children, both
for professionals and families. Properly tested medica-
tions will be marked with a logo (the letter ‘P’ in blue
lettering, surrounded by an outline of a star, also in blue),
providing transparency about processes.
The paediatric investigation plan is to become an integral
part of the introduction of all medicines in the EU. It should
be submitted early. It must include details of which sub-
populations of children will be studied. It may be ap-
propriate to delay research in children until there is
experience in adults, but early dialogue with the Paediatric
Committee will be essential. The plan may be deferred or
waived, but only with the agreement of the Committee. The
Committee will have the power to revoke the waiver, and
will be consulted about compliance with the Investigation
prior to the granting of market authorization. The Com-
mittee will mark with a symbol medication which has been
tested in children. Furthermore, companies will be obliged
to place the product on the market within two years of
approval, and must notify the Committee if they propose to
withdraw them.
Waivers would be on the grounds that the medication is
likely to be ineffective, unsafe, or irrelevant (the disease does
not occur in children); or offers no new benefit to children.
Deferral would usually be because it is appropriate to
perform the studies in adults first, or paediatric studies will
take so long that there would be an unacceptable delay in
marketing for adults. The rewards will include a 6 month
extension of patent if companies have submitted a paediatric
Plan and adhered to it appropriately, even if it transpires that
the medication is not suitable for children and a licence is not
authorised. Rewards will be withheld if Investigation Plans
are flouted. Furthermore, there will be penalties which are as
yet unspecified, but will be ‘effective, proportionate, and
dissuasive’. Those infringing will be named publicly.
A similar system will exist for off-patent medicines: the
Paediatric Use Marketing Authorisation (PUMA). For
orphan drugs, the granted 10 years period of marketing
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data is provided. For medicines where these incentives have
not led to appropriate research in children, the EU proposes
to fund research under the Medicines Investigation for the
Children of Europe (MICE) programme.
In addition to statutory incentives, the paediatric research
community needs access to a publicly available database of
proposed and ongoing clinical trials. The EudraCT database
has been established under the EU clinical trials directive
[European Parliament and the Council of the European
Union 2001] and provides limited information regarding
ongoing trials. More detailed information on paediatric trials
is provided by DECnet (http://www.dec-net.org/).
6. The Clinical Trial Network (CTN)
6.1. What is the primary purpose and the structure of the
CTN and how does it relate to Clinical Trials Centres
(CTC), sponsors and regulators?
There is consensus that a European clinical Trial Network
(CTN) should be formed. The intention of ECFS is to create
a CTN to optimize the development and evaluation of new
and approved treatments for CF in clinical studies in Europe.
The CTN will give advice on optimal study design, including
recruitment of eligible patient groups, statistical methodol-
ogy and standardization of outcome measures and promote
safety of participants in clinical trials involving CF patients.
The CTN will consist of an Coordinating Body (CB) and
Clinical Trial Centres (CTC)s. The ECFS board in
collaboration with appropriate patient organizations will
appoint a working group. This working group will define
structure and functions of the CB and criteria for
accreditation of the CTCs. The established CTN will be
governed by a steering committee (SC) which among others
includes representatives from the CTCs. The CTCs will
conduct clinical trials within CTN by providing appropriate
personnel, facilities equipment, materials and services and
access to eligible CF populations. The CTN will collaborate
with member state CTNs and internationally with other non-
European clinical trial organizations such as the CFF TDN. It
is the intention of CTN to include interpretive centres and
central laboratories, if necessary. CTN will communicate
closely and cooperate with the EMEA (EMA).
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